You are here

Less Than Two-Thirds of Pharmacy Directors Expect to Reimburse Both Saxagliptin and Alogliptin Once Available

NASHVILLE, Tenn. and GLEN ROCK, N.J., Feb. 2 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that less than two-thirds of surveyed pharmacy directors expect to reimburse both Bristol-Myers Squibb/AstraZeneca's Onglyza and Takeda's alogliptin once they become available. Sixty-two percent of surveyed pharmacy directors say they expect their managed care organization to reimburse both products, while 26 percent say they expect their organization to reimburse only one. Seventy-eight percent of surveyed pharmacy directors say it is either likely or very likely they will reimburse Novo Nordisk's Victoza upon FDA approval.

According to the new Formulary Forum report entitled Formulary Advantages in Type 2 Diabetes: Impact of Current and Future DPP-IV Inhibitors and GLP-1 Analogues on Advantaged Reimbursement Status for Key Brands, 62 percent of surveyed pharmacy directors say their managed care organization would place Onglyza or alogliptin on Tier 1 or 2 if the agent were priced at $4.00 per treated day, but fewer (24 percent) would place it on Tier 1 or 2 if priced at $5.00 per treated day.

The report also finds that more surveyed pharmacy directors say that contract negotiations are important when improving the formulary position of Merck's Januvia and Amylin/Eli Lilly's Byetta than say safety or efficacy gains leading to downstream cost savings. Both recent entrants in the antidiabetic market, Januvia and Byetta are covered on 85 percent of health plans.

"Our survey reveals that contracting is a leading factor for pharmacy directors looking at products in the antidiabetic market," said Michael Malecki, Ph.D., business analyst with HealthLeaders-InterStudy. "Determining the optimal pricing 'sweet spot' will be important to drive uptake of emerging agents."

About Formulary Advantages in Type 2 Diabetes: Impact of Current and Future DPP-IV Inhibitors and GLP-1 Analogues on Advantaged Reimbursement Status for Key Brands

The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level managed care organizations (MCO). Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows easy visualization of data and easy incorporation of material into presentations.

Source: HealthLeaders-InterStudy

Recent Headlines

Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring
Finding Could Spur New Targeted Treatments
But a ‘Serendipitous’ Finding Could Provide a Solution
New Drug Could Make Ears “Young” Again
DNA Changes May Help Predict Women at Risk